![](https://pf-media.co.uk/wp-content/uploads/2024/07/Drug-Launches_696x464_2-4.jpg)
Non-small cell lung cancer drug approval
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of a drug for patients with non-small cell lung cancer. The approval is for a type II extension of indication for RYBREVANT®▼ ( …